Gain Therapeutics Framtida tillväxt
Future kriterier kontrolleras 0/6
Gain Therapeutics förväntas öka vinsten och intäkterna med 30.7% och 55.9% per år respektive medan EPS förväntas växa med 32.9% per år.
Viktig information
30.7%
Tillväxttakt i vinsten
32.93%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 25.0% |
| Intäkternas tillväxttakt | 55.9% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 28 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Analysartikel • May 27
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.Analysartikel • May 22
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.Analysartikel • May 05
3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.
Ny berättelse • Apr 01
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Seeking Alpha • Nov 07
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Summary Gain Therapeutics achieved functional improvement in Parkinson’s patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287’s mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX’s $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions. I reiterate a Strong Buy rating for GANX. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Summary Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson’s disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. Read the full article on Seeking AlphaSeeking Alpha • May 29
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors. Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space. Read the full article on Seeking AlphaSeeking Alpha • Jan 12
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Summary Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset. Gain's stock has been performing well, and similarities with a recent acquisition of Caraway Therapeutics by Merck may confirm its undervaluation. Read the full article on Seeking AlphaSeeking Alpha • Sep 20
Gain Therapeutics appoints CEO
Biotechnology company Gain Therapeutics (NASDAQ:GANX) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight members. Richman will continue to serve as a board member and as a senior advisor. Source: Press ReleaseSeeking Alpha • Oct 27
Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated either by trial data or major investment. Gain has not yet had an IND accepted by the FDA, but targets include GM1 Gangliosidosis, Parkinson's, and Gaucher Disease. There are areas of high unmet need and competitive fields, but Gain does at least have some promising preclinical data. The $7 per share entry point feels cheap to me, with numerous upcoming catalysts, an experienced management team and Board, and oral availability all plus points.Seeking Alpha • Aug 19
Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with multiple value inflections expected. Management has a track record of creating value through pharma partnerships and exits. Approaching top-line data for lead compound in GBA1 Parkinson’s has game-changing potential.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | N/A | -33 | N/A | N/A | 2 |
| 12/31/2027 | N/A | -36 | N/A | N/A | 5 |
| 12/31/2026 | N/A | -24 | N/A | N/A | 5 |
| 3/31/2026 | N/A | -21 | -19 | -19 | N/A |
| 12/31/2025 | N/A | -20 | -18 | -18 | N/A |
| 9/30/2025 | N/A | -19 | -17 | -17 | N/A |
| 6/30/2025 | N/A | -19 | -18 | -18 | N/A |
| 3/31/2025 | N/A | -21 | -19 | -19 | N/A |
| 12/31/2024 | N/A | -20 | -19 | -19 | N/A |
| 9/30/2024 | N/A | -21 | -21 | -21 | N/A |
| 6/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 3/31/2024 | N/A | -21 | -18 | -18 | N/A |
| 12/31/2023 | 0 | -22 | -19 | -19 | N/A |
| 9/30/2023 | 0 | -22 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -22 | -17 | -16 | N/A |
| 3/31/2023 | 0 | -19 | -17 | -16 | N/A |
| 12/31/2022 | 0 | -18 | -15 | -15 | N/A |
| 9/30/2022 | 0 | -16 | -15 | -15 | N/A |
| 6/30/2022 | 0 | -16 | -14 | -14 | N/A |
| 3/31/2022 | 0 | -15 | -12 | -12 | N/A |
| 12/31/2021 | 0 | -14 | -12 | -12 | N/A |
| 9/30/2021 | 0 | -12 | -10 | -10 | N/A |
| 6/30/2021 | 0 | -8 | -8 | -8 | N/A |
| 3/31/2021 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -4 | -3 | -3 | N/A |
| 9/30/2020 | N/A | -3 | -2 | -2 | N/A |
| 12/31/2019 | N/A | -2 | N/A | -2 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: GANX förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: GANX förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: GANX förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: GANX förväntas inte ha några intäkter nästa år.
Hög tillväxtintäkter: GANX förväntas inte ha några intäkter nästa år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om GANX s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/05 00:53 |
| Aktiekurs vid dagens slut | 2026/06/05 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Gain Therapeutics, Inc. bevakas av 7 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |